Trending

IBD

PREDiCT: Autoimmune Disease Modeling Summit

PREDiCT: Autoimmune Disease Modeling Summit

Deploy Advanced Models to Enhance Your Confidence & Und

X

PREDiCT: Autoimmune Disease Modeling Summit

https://pharmaphorum.com/events/predict-autoimmune-disease-modeling-summit/

Celltrion gears up for subcutaneous infliximab launch in Europe

Celltrion gears up for subcutaneous infliximab launch in Europe

Celltrion Healthcare’s subcutaneous (SC) formulation of its infliximab biosimilar, codenamed CT-P13 SC, looks set to launch in Europe

X

Celltrion gears up for subcutaneous infliximab launch in Europe

https://pharmaphorum.com/views-analysis-market-access/celltrion-gears-up-for-subcutaneous-infliximab-launch-in-europe/

Takeda proposes selling Shire’s IBD treatment after merger

Takeda proposes selling Shire’s IBD treatment after merger

Takeda has proposed selling off a Shire treatment for inflammatory bowel disease when the companies merge next year,

X

Takeda proposes selling Shire’s IBD treatment after merger

https://pharmaphorum.com/news/takeda-proposes-selling-shires-ibd-treatment-after-merger/

FDA approves oral treatment for ulcerative colitis

FDA approves oral treatment for ulcerative colitis

Pfizer’s janus kinase (JAK) inhibitor drug Xeljanz (tofacitinib) has received expanded approval from the FDA for adults with moderately-to-severely-active ulcerative colitis.

X

FDA approves oral treatment for ulcerative colitis

https://pharmaphorum.com/news/fda-oral-treatment-ulcerative-colitis/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com